Free Trial

HC Wainwright Issues Positive Outlook for CRGX Earnings

CARGO Therapeutics logo with Medical background

CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) - Stock analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for CARGO Therapeutics in a report released on Thursday, January 30th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.61) per share for the quarter, up from their prior estimate of ($0.97). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for CARGO Therapeutics' current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for CARGO Therapeutics' Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.06) EPS.

CARGO Therapeutics (NASDAQ:CRGX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.26.

Other analysts have also issued research reports about the company. Chardan Capital lowered CARGO Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, January 30th. Truist Financial lowered CARGO Therapeutics from a "buy" rating to a "hold" rating and reduced their price target for the company from $32.00 to $7.00 in a research report on Thursday, January 30th. Jefferies Financial Group downgraded CARGO Therapeutics from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $32.00 to $3.00 in a research report on Thursday, January 30th. Piper Sandler downgraded shares of CARGO Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $34.00 to $4.00 in a research note on Thursday, January 30th. Finally, William Blair downgraded shares of CARGO Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat.com, CARGO Therapeutics currently has an average rating of "Hold" and an average price target of $15.00.

Check Out Our Latest Report on CARGO Therapeutics

CARGO Therapeutics Trading Down 0.5 %

CRGX traded down $0.02 during trading hours on Monday, hitting $3.70. 907,160 shares of the company's stock were exchanged, compared to its average volume of 1,667,530. The firm has a market cap of $170.31 million, a P/E ratio of -0.87 and a beta of 2.12. CARGO Therapeutics has a 12-month low of $3.00 and a 12-month high of $33.92. The firm has a 50 day moving average of $13.47 and a 200 day moving average of $16.95.

Hedge Funds Weigh In On CARGO Therapeutics

Several hedge funds have recently added to or reduced their stakes in CRGX. Brooklyn Investment Group purchased a new stake in shares of CARGO Therapeutics in the 4th quarter valued at about $27,000. China Universal Asset Management Co. Ltd. acquired a new position in CARGO Therapeutics during the fourth quarter worth approximately $141,000. BNP Paribas Financial Markets lifted its stake in CARGO Therapeutics by 437.8% in the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company's stock valued at $211,000 after buying an additional 9,311 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of CARGO Therapeutics in the third quarter valued at approximately $234,000. Finally, JPMorgan Chase & Co. grew its position in shares of CARGO Therapeutics by 74.9% during the third quarter. JPMorgan Chase & Co. now owns 15,007 shares of the company's stock worth $277,000 after acquiring an additional 6,426 shares during the last quarter. 93.16% of the stock is currently owned by hedge funds and other institutional investors.

CARGO Therapeutics Company Profile

(Get Free Report)

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.

Read More

Should You Invest $1,000 in CARGO Therapeutics Right Now?

Before you consider CARGO Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CARGO Therapeutics wasn't on the list.

While CARGO Therapeutics currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The EXACT Date of Next Stock Market Crash
HIMS Stock Up 120%! More Growth Ahead?
How to Find the BEST Penny Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines